NLS Pharmaceutics and Kadimastem receive Nasdaq approval for merger Oct 23, 2025 06:03AM
NLS Pharmaceutics shareholders approve merger with Kadimastem Sep 30, 2025 07:01AM
Kadimastem receives Hong Kong patent for diabetes therapy technology Sep 4, 2025 07:39AM
NLS Pharmaceutics (NLSP) CEO Issues Letter to Shareholders Mar 10, 2025 07:04AM
NLS Pharmaceutics (NLSP) Launches a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence Jan 28, 2025 07:32AM